In the last full year, REGENERON PHARMACEUTICALS, INC. recorded 2 award actions totaling -331.71 million in obligated value, with an average action value of -165.85 million. All reported obligations in this window were tied to the Administration for Strategic Preparedness and Response and NAICS 541711, Research and Development in Biotechnology.
Federal Contractor
REGENERON PHARMACEUTICALS, INC. Federal Contract Obligations (Last Year)
Federal procurement profile for REGENERON PHARMACEUTICALS, INC. (CAGE 544P9, UEI N3F9MH7E6HD6) covering the last full year of award activity.
Values reflect the provided last-full-year FPDS summary, including negative obligated amounts and rounded readable totals.
CAGE Code
544P9
UEI
N3F9MH7E6HD6
Total Obligated
-331.71 million
-331,708,160.10
Award Actions
2
Average Action Value
-165,854,080.05
About REGENERON PHARMACEUTICALS, INC. federal contract activity
In the last full year, REGENERON PHARMACEUTICALS, INC. recorded 2 FPDS awards tied to a net obligated value of -$331.71 million, producing an average award value of -$165.85 million. The negative total obligated amount should be read in context of obligation adjustments rather than as a simple measure of spend volume.
Agency mix and customer concentration
All recorded obligated activity in the period is concentrated in a single agency, the Administration for Strategic Preparedness and Response (agency ID 7505), which accounts for the full -$331.71 million across 2 awards. This indicates a highly concentrated federal customer profile for the analysis window, with no other agencies represented in the provided data.
Industry profile based on NAICS activity
The vendor’s obligated activity is likewise concentrated in one NAICS category: 541711, Research and Development in Biotechnology. That sector represents the full award count and total obligated value in the period, suggesting the recorded federal business was entirely aligned to biotechnology R&D.
Annual contract trend over the analysis window
The annual trend shows all recorded activity in 2025, with -$331.71 million obligated across 2 awards. With only one year represented, the available data indicates a single-period concentration rather than a multi-year pattern.
How to interpret this page
This summary uses the provided FPDS Query aggregates for the last full year, including total obligated, award count, average award value, agency concentration, NAICS distribution, and annual trend. Values are reported as supplied; negative obligated amounts are preserved because they reflect FPDS obligation accounting rather than a normalized spend metric.
Top Agencies
SELECT
agency_id,
agency_name,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
content__award__purchaserInformation__contractingOfficeAgencyID AS agency_id,
anyHeavy(content__award__purchaserInformation__contractingOfficeAgencyID__name) AS agency_name,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__vendor__vendorSiteDetails__entityIdentifiers__cageCode = '544P9'
AND content__award__purchaserInformation__contractingOfficeAgencyID IS NOT NULL
AND content__award__purchaserInformation__contractingOfficeAgencyID != ''
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 1 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY agency_id
)
ORDER BY total_obligated DESC
LIMIT 10| Agency ID | Agency Name | Total Obligated | Readable | Award Actions |
|---|---|---|---|---|
| 7505 | ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE | -331,708,160.10 | -331.71 million | 2 |
Insight
Over the last full year, REGENERON PHARMACEUTICALS, INC. recorded -$331.71 million in net obligated value across 2 awards, with an average award value of -$165.85 million. All reported obligations are concentrated in a single agency, the Administration for Strategic Preparedness and Response (7505), indicating complete agency-level concentration in this window. This distribution suggests the vendor’s federal activity for the period was highly focused rather than spread across multiple agencies.
Top NAICS
SELECT
naics_code,
naics_name,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
content__award__productOrServiceInformation__principalNAICSCode AS naics_code,
anyHeavy(content__award__productOrServiceInformation__principalNAICSCode__description) AS naics_name,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__vendor__vendorSiteDetails__entityIdentifiers__cageCode = '544P9'
AND content__award__productOrServiceInformation__principalNAICSCode IS NOT NULL
AND content__award__productOrServiceInformation__principalNAICSCode != ''
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 1 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY naics_code
)
ORDER BY total_obligated DESC
LIMIT 10| NAICS Code | Description | Total Obligated | Readable | Award Actions |
|---|---|---|---|---|
| 541711 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY | -331,708,160.10 | -331.71 million | 2 |
Insight
REGENERON PHARMACEUTICALS, INC. (CAGE 544P9) shows complete concentration in NAICS 541711, Research and Development in Biotechnology, for the last full year. The vendor recorded two awards totaling -$331.71 million, indicating all reported obligation in this window is tied to a single NAICS category. This pattern suggests a highly concentrated award profile with no diversification across other NAICS codes in the period reviewed.
Annual Trend
SELECT
year,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
toYear(parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate)) AS year,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__vendor__vendorSiteDetails__entityIdentifiers__cageCode = '544P9'
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 1 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY year
)
ORDER BY year DESC| Year | Total Obligated | Readable | Award Actions |
|---|---|---|---|
| 2025 | -331,708,160.10 | -331.71 million | 2 |
Insight
During the last full year, REGENERON PHARMACEUTICALS, INC. (CAGE 544P9) recorded $331.71 million in net deobligations across 2 awards, indicating highly concentrated activity in a very small number of actions. The average award value of -$165.85 million suggests the annual movement was driven by two large obligation adjustments rather than broad transactional volume. With only one year in scope, the available data supports a snapshot of concentrated downward funding movement, not a multi-year trend.
Use FPDS Query for deeper contractor analysis
Explore federal procurement data with custom SQL, fast filtering, and deeper contractor analysis across buying agencies, NAICS, and annual trends.
Continue from this last full year view into full FPDS Query workflows with deeper filtering, custom SQL, saved queries, and broader market comparison.